3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Phase 3
1
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Polycystic Ovary Syndrome
21
Insulin Resistance
5
Obesity
4
Neoplasms
3
Prostatic Neoplasms
2
Motor Activity
2
Menstruation Disturbances
2
Medulloblastoma
2
Infertility
2
Diabetes Mellitus
2
Breast Neoplasms
2
Weight Loss
1
Vitamin D Deficiency
1
Triple Negative Breast Neoplasms
1
Toxemia
1
Thyroid Neoplasms
1
Premature Birth
1
Pregnancy Complications
1
Prediabetic State
1
Pre-Eclampsia
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Non-DM Stage II High-risk Colorectal Cancer
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Metabolic Syndrome
1
Liver Neoplasms
1
Infertility, Female
1
Hyperinsulinism
1
Hyperandrogenism
1
Interventions
Paclitaxel
79
Carboplatin
64
Bevacizumab
33
liposomal doxorubicin
29
Topotecan
28
Gemcitabine
25
Cisplatin
19
olaparib
18
Drug Therapy
12
Doxorubicin
12
Taxes
11
niraparib
9
Docetaxel
6
CP protocol
6
Trabectedin
5
Hyperthermic Intraperitoneal Chemotherapy
5
Etoposide
5
Cyclophosphamide
5
1-dodecylpyridoxal
5
rucaparib
4
pembrolizumab
4
avelumab
4
atezolizumab
4
Immunoglobulin G
4
Ifosfamide
4
Disulfides
4
Dexamethasone
4
Chemotherapy, Adjuvant
4
trebananib
3
fluzoparib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Ovarian Neoplasms
×
Metformin
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn